Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding

Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery

“…These Fc-engineered variants may be used as fusion partners for therapeutic proteins, such as antidiabetic peptides, to achieve extended half-life and improved bioavailability. Preclinical examples are the combination of Fc-containing YTE or LS variants fused to cytotoxic T lymphocyte-associated protein 4, where both Fc fusion products yielded more than 2-fold extended half-life in non-human primates [185,186]. In addition, in vitro studies on transcytosis have demonstrated that Fc-engineering can enhance delivery across polarized epithelial cell monolayers, as shown for hIgG1 antibodies containing LS or YTE substitutions that were transported almost twice as efficiently across human epithelial cells as the WT counterpart [43].…”